Guardant Health joins forces with James Van Der Beek to raise colorectal cancer awareness

 

     

Guardant Health, a precision oncology company, has announced a partnership with actor and health advocate James Van Der Beek to raise awareness about colorectal cancer (CRC) screening.

Van Der Beek, who went public with his own CRC diagnosis in November 2024, is now speaking out about the critical importance of staying up-to-date with screening guidelines. This collaboration aims to highlight advances in CRC screening, particularly Guardant Health's FDA-approved Shield™ blood test.

   

The Shield™ test offers a convenient and less invasive screening option for adults aged 45 and older at average risk for CRC, requiring only a simple blood draw. This initiative addresses the fact that many CRC deaths occur in patients who have not been screened, often due to traditional methods being perceived as unpleasant or inconvenient.

Colorectal cancer is a significant health concern, with over 50,000 Americans dying from the disease each year. Early detection is crucial, as the five-year survival rate is over 90% when CRC is caught in its early stages, but drops significantly in late stages.